Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. The method according to claim 3, in which said at least one immunoglobulin single variable domain essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
i) CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90, and CDR3 is SEQ ID NO: 118; or
ii) CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90, and CDR3 is SEQ ID NO: 123.